Here is how Centene (CNC) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Centene $CNC (CNC) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Centene is a member of the Medical sector. This group includes 888 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Centene is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for CNC's full-year earnings has moved 19.9% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, CNC has gained about 34.5% so far this year. At the same time, Medical stocks have lost an average of 6.8%. As we can see, Centene is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Cellectar Biosciences, Inc. (CLRB). The stock has returned 19.7% year-to-date.
For Cellectar Biosciences, Inc., the consensus EPS estimate for the current year has increased 59.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Centene is a member of the Medical - HMOs industry, which includes 8 individual companies and currently sits at #53 in the Zacks Industry Rank. On average, stocks in this group have gained 9.9% this year, meaning that CNC is performing better in terms of year-to-date returns.
On the other hand, Cellectar Biosciences, Inc. belongs to the Medical - Products industry. This 78-stock industry is currently ranked #152. The industry has moved -23.2% year to date.
Investors interested in the Medical sector may want to keep a close eye on Centene and Cellectar Biosciences, Inc. as they attempt to continue their solid performance.
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X $TWTR Imaging which shot up +129.6% in little more than 9 months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Centene Corporation (CNC): Free Stock Analysis Report
Cellectar Biosciences, Inc. (CLRB): Free Stock Analysis Report
Join 500,000+ readers who start their day with Quartz.
By subscribing, you agree to our Terms of Service and Privacy Policy.
